The role of combination chemotherapy has not yet been established in unresectable locally advanced pancreatic cancer (LAPC) lacking dedicated randomized trials.
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trial / Cascinu, S., Berardi, R., Bianco, R., Bilancia, D., Zaniboni, A., Ferrari, D., Mosconi, S., Spallanzani, A., Cavanna, L., Leo, S., Negri, F., Beretta, G.D., Sobrero, A., Banzi, M., Morabito, A., Bittoni, A., Marciano, R., Ferrara, D., Noventa, S., Piccirillo, M.C., et al.. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 1879-0852. - 148:(2021), pp. 422-429. [10.1016/j.ejca.2021.02.023]
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trial
Bianco, Roberto;Marciano, Roberta;Gallo, Ciro;Perrone, Francesco
2021
Abstract
The role of combination chemotherapy has not yet been established in unresectable locally advanced pancreatic cancer (LAPC) lacking dedicated randomized trials.| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S0959804921001064-main.pdf
accesso aperto
Tipologia:
Versione Editoriale (PDF)
Licenza:
Copyright dell'editore
Dimensione
890.78 kB
Formato
Adobe PDF
|
890.78 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
